Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission.

Saved in:
Bibliographic Details
Title: Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission.
Authors: Gamerith G; Department of Internal Medicine V, Hematology and Oncology, Comprehensive Cancer Center Innsbruck (CCCI), Medical University of Innsbruck, Innsbruck, Austria., Mildner F; Department of Internal Medicine V, Hematology and Oncology, Comprehensive Cancer Center Innsbruck (CCCI), Medical University of Innsbruck, Innsbruck, Austria., Merkel PA; Division of Rheumatology and Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Harris K; Immune Tolerance Network (ITN), Bethesda, Maryland, USA., Cooney L; Immune Tolerance Network (ITN), Bethesda, Maryland, USA., Lim N; Immune Tolerance Network (ITN), Bethesda, Maryland, USA., Spiera R; Hospital for Special Surgery, New York City, New York, USA., Seo P; Department of Internal Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA., Langford CA; Rheumatic and Immunologic Diseases, Cleveland Clinic Foundation, Cleveland, Ohio, USA., Hoffman GS; Rheumatic and Immunologic Diseases, Cleveland Clinic Foundation, Cleveland, Ohio, USA., St Clair EW; Rheumatology, Duke University School of Medicine, Durham, North Carolina, USA., Fervenza FC; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA., Monach P; VA Boston Healthcare System, West Roxbury, Massachusetts, USA., Ytterberg SR; Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA., Geetha D; Division of Nephrology, Johns Hopkins University, Baltimore, Maryland, USA., Amann A; Department of Internal Medicine V, Hematology and Oncology, Comprehensive Cancer Center Innsbruck (CCCI), Medical University of Innsbruck, Innsbruck, Austria., Wolf D; Department of Internal Medicine V, Hematology and Oncology, Comprehensive Cancer Center Innsbruck (CCCI), Medical University of Innsbruck, Innsbruck, Austria., Specks U; Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, New York, USA., Stone JH; Rheumatology Unit, Division of Rheumatology Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA., Kronbichler A; Department of Medicine, University of Cambridge, Cambridge, UK ak2283@cam.ac.uk.
Source: Annals of the rheumatic diseases [Ann Rheum Dis] 2023 Feb; Vol. 82 (2), pp. 253-261. Date of Electronic Publication: 2022 Aug 16.
Publication Type: Randomized Controlled Trial; Journal Article
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 0372355 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-2060 (Electronic) Linking ISSN: 00034967 NLM ISO Abbreviation: Ann Rheum Dis Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1468-2060
DOI:10.1136/ard-2022-222479